Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(18 intermediate revisions by 2 users not shown)
Line 1: Line 1:
Welcome!
Ian Welcome!


'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
Line 1,403: Line 1,403:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|Disease
|Karin Miller, MD
|To be covered in B-ALL, NOS
|10/9/2025
|
|
|
|
|
Line 1,422: Line 1,422:
|
|
|
|
|
|Complete (pending review by SK)
|
|
|SK
|SK
Line 1,438: Line 1,438:
|
|
|
|
|
|Complete (pending review by SK)
|
|
|SK
|SK
Line 1,452: Line 1,452:
|Disease
|Disease
|Holli Drendel, PhD
|Holli Drendel, PhD
|Nov 11/2025
|
|
|
|Pending
|?Complete? Looks like tables need more editing.
|
|
|SK
|SK
Line 1,469: Line 1,469:
|Karin Miller, MD
|Karin Miller, MD
|10/9/2025
|10/9/2025
|
|12/5/2025
|
|
|
|
Line 1,483: Line 1,483:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Disease
|Mark G. Evans, MD; Kilannin Krysiak, PhD
|Mark G. Evans, MD
|10/1/2025
|10/1/2025
|11/17/2025
|11/17/2025
|Complete (pending review by SK)
|11/8/2025
|SK
|Pending
|Pending
|
|SK
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
Line 1,583: Line 1,583:
|10/10/2025
|10/10/2025
|11/24/2025
|11/24/2025
|Complete (pending SK review)
|11/11/2025
|SK
|Pending
|Pending
|
|SK
|
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 1,598: Line 1,598:
|Lei Zhang, PhD
|Lei Zhang, PhD
|10/10/2025
|10/10/2025
|
|12/22/2025
|Pending
|Pending
|
|
Line 1,611: Line 1,611:
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease (See [https://ccga.io/index.php/HAEM5:B-lymphoblastic_leukaemia/lymphoma B-lymphoblastic leukaemia/lymphoma])
|Disease  
|Karin Miller, MD
|10/9/2025
|11/24/2025
|Pending
|
|
----
|SK
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
|
----
|
----
|
----
|
----
|
----
|
----
|-
|-
!Disease (5th Edition)
!Disease (5th Edition)
Line 2,448: Line 2,435:
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|-
|-
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| || || || || ||Sumi Kitahara (SK)
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK)
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,459: Line 2,446:
Karin Miller, MD
Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,485: Line 2,473:
|
|
|
|
|Pending
|
|
|
|SK
|SK
Line 2,499: Line 2,487:
|Disease
|Disease
|Parastou Tizro, MD;
|Parastou Tizro, MD;
Celeste Eno, PhD
Celeste Eno, PhD; Sumire Kitahara, MD
|9/23/2025
|9/23/2025
|11/4/2025
|11/4/2025
|Pending
|'''Complete'''
|Old template completed 6/24/2024
|11/4/2025
|SK
|SK
|7/1/2024
|11/6/2025
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 2,529: Line 2,517:
|9/24/2025
|9/24/2025
|12/9/2025
|12/9/2025
|Pending
|'''Complete'''
| ||SK|| ||
| 12/17/2025||SK|| 1/6/2026||
|Chronic Lymphoproliferative Disorder of NK Cells
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Michelle Don, MD
Line 2,550: Line 2,538:
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|3/22/2024
| || || ||SK|| ||
|follow-up needed
| || ||SK|| ||
|Sézary Syndrome
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,557: Line 2,546:
|
|
|-
|-
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|10/15/2025||1/19/2026
|7/1/2024||8/31/2024
|Pending
|Pending
| ||SK|| ||
| ||SK|| ||
Line 2,584: Line 2,572:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc; Teodora Popa (resident)
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD
|3/19/2024
|1/6/2026
| ||Pending
| 2/3/2026||
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,598: Line 2,586:
Andrew Siref, MD
Andrew Siref, MD
|10/14/2025
|10/14/2025
| ||Pending
|11/24/2025
| ||SK|| ||
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,608: Line 2,597:
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|3/22/2024
| || || ||SK|| ||
|follow-up needed|| || ||SK|| ||
|Mycosis Fungoides
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Jane Scribner, MD and Daynna J. Wolff, PhD
Line 2,618: Line 2,607:
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024
|7/1/2024
|8/31/224
|follow-up needed
|Pending
|
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,629: Line 2,618:
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
Shashirekha Shetty, PhD
|7/1/2024||8/31/2024
|7/1/2024||follow-up needed
|Pending
|
| ||SK|| ||
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Primary Cutaneous Anaplastic Large Cell Lymphoma
Line 2,638: Line 2,627:
|
|
|-
|-
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD
|3/19/2024
Katelyn Swanson, DO (trainee)
| ||Pending
|11/19/2025
| ||SK|| ||
|12/19/2025
|'''Complete'''
| 1/6/2026||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,651: Line 2,642:
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/30/2024
|6/30/2024
| ||Pending
|11/9/2025
|Pending
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,662: Line 2,654:


Andrew Siref, MD
Andrew Siref, MD
|10/14/2025|| ||Pending
|10/14/2025||11/24/2025
| ||SK|| ||
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,740: Line 2,733:
|9/24/2025
|9/24/2025
|11/9/2025
|11/9/2025
|Pending
|'''Complete'''
|Old template completed 5/13/24||SK||10/18/24||
|12/17/2025
|SK||1/6/2026||
|Hepatosplenic T-cell Lymphoma
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Michelle Don, MD, MS
Line 2,751: Line 2,745:


Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Anaplastic Large Cell Lymphoma, ALK-Positive
Line 2,765: Line 2,759:
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
Sumire Kitahara, MD
|6/6/24|| ||Pending
|6/6/24|| ||
| ||SK|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Anaplastic Large Cell Lymphoma, ALK-Negative
Line 2,800: Line 2,794:
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
| ||Pending|| ||SK|| ||prior authors not available
|follow-up needed
| || ||SK|| ||prior authors not available
|Angioimmunoblastic T-cell Lymphoma
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
Line 2,808: Line 2,803:
|-
|-
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
| ||Pending|| ||SK|| ||
|follow-up needed
| || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,824: Line 2,820:
|-
|-
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|6/25/2023
|10/14/2025
| || || ||SK|| ||
|12/3/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,841: Line 2,839:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc;
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD
Teodora Popa (resident)
|1/6/2026
|3/19/2024
| 2/3/2026||Pending
| ||Pending
| ||SK|| ||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
Line 2,868: Line 2,865:
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||
| 11/17/2025||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 2,877: Line 2,875:
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
|3/25/2024
| || || ||SK|| ||prior authors not available
| 11/17/2025||Pending
| ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"